Odonate Therapeutics, Inc.$1.12 %
Analyst Rating: Hold
Stock Details
CEO
Kevin Tang
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
137
Address
4747 Executive Dr Ste 510, San Diego, CA, 10016
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Top Competitors
Income Statement
Financials
Selected Year
Revenue Estimates
EPS Estimates
Net Income Estimates
Price target for Odonate Therapeutics, Inc. $1.12
$0
Min Forecast(+0% )
$249.61
Avg Forecast( +0% )
$325
Max Forecast(+0%)
EPS
Revenue
Institutional Holder
Loading institutional holder data...
Congress Tracker
Showing 0 of 0 results
Insider Trading of Key Employees
Showing 0 of 0 results